Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases
Top Cited Papers
Open Access
- 18 December 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Abstract
Previous advances have identified immune pathways associated with inflammatory skin diseases, leading to the development of targeted therapies. However, there is a lack of molecular approaches that delineate these pathways at the individual patient level for personalized diagnostic and therapeutic guidance. Here, we conduct a cross-comparison of expression profiles from multiple inflammatory skin diseases to identify gene modules defining relevant immune pathways. Seven modules are identified, representing key immune pathways: Th17, Th2, Th1, Type I IFNs, neutrophilic, macrophagic, and eosinophilic. These modules allow the development of a molecular map with high diagnostic efficacy for inflammatory skin diseases and clinico-pathologically undetermined cases. Aligning dominant modules with treatment targets offers a rational framework for treatment selection, improving response rates in both treatment-naïve patients and non-responders to targeted therapies. Overall, our approach offers precision medicine for inflammatory skin diseases, utilizing transcriptional modules to support diagnosis and guide personalized treatment selection.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030B_182834, 310030_204835, 4078P0_198470)
- Fondation Leenaards
This publication has 50 references indexed in Scilit:
- Evaluation of Dupilumab in Patients With Bullous PemphigoidJAMA Dermatology, 2023
- Cross-Comparison of Inflammatory Skin Disease Transcriptomics Identifies PTEN as a Pathogenic Disease Classifier in Cutaneous Lupus ErythematosusJournal of Investigative Dermatology, 2023
- Spesolimab use in treatment of pyoderma gangrenosumJAAD Case Reports, 2023
- Treatment of severe lichen planus with the JAK inhibitor tofacitinibJournal of Allergy and Clinical Immunology, 2020
- Atopic dermatitis endotypes and implications for targeted therapeuticsJournal of Allergy and Clinical Immunology, 2019
- Psoriasis: from Pathogenesis to Targeted TherapiesClinical Reviews in Allergy & Immunology, 2018
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trialsThe Lancet, 2017
- The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapiesJournal of Allergy and Clinical Immunology, 2017
- HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis ProgramJournal of Investigative Dermatology, 2016
- Safety and Efficacy of Anakinra in Severe Hidradenitis SuppurativaJAMA Dermatology, 2016